THYROCARE Thyrocare Technologies Q1 FY27 results (Apr–Jun 2026) and concall
Thyrocare Technologies Limited reported a strong Q1 FY27, with consolidated revenue growing 24.3% and PAT increasing 34% YoY. The pathology business continued its robust growth, and the franchisee network expanded significantly. The company is strategically focusing on scaling its specialty diagnostics business and intends to divest its dilutive radiology segment, while the parent company continues to reduce its debt.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q1 FY27: revenue up 24.4%, net profit up 34.2% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 177 | 166 | 187 | 193 | 217 +23% | 196 +18% | 224 +20% | 240 +24% |
| EBITDA | 48 | 42 | 57 | 58 | 71 +48% | 58 +38% | 75 +32% | 77 +33% |
| Net profit | 26 | 19 | 22 | 38 | 48 +85% | 28 +47% | 49 +123% | 51 +34% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
